European Innovation Council

Basemark Oy is a company based in Espoo, Finland, specializing in performance measurement tools and services for various industries, including mobile devices and automotive applications. Founded in 2015, it provides a range of benchmarking tools such as Basemark ES 3.1 for graphics performance comparisons, Basemark OS II for system-level performance measurement across platforms like Android and iOS, and Basemark X for evaluating gaming and graphics performance. Additionally, Basemark offers Browsermark for testing browser performance on multiple devices, as well as Basemark CL for measuring OpenCL implementations. The company also focuses on augmented reality (AR) software for the automotive sector, enabling original equipment manufacturers (OEMs) to develop advanced AR applications for vehicle functions, including navigation and heads-up displays. Basemark's tools support both benchmarking and AR development, catering to the needs of device manufacturers and semiconductor companies.

Valo Therapeutics is an immunotherapy company based in Oxford, United Kingdom, with an additional office in Helsinki, Finland. Founded in 2016, the company focuses on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Its primary platform, PeptiCRAd, is an engineered human oncolytic adenovirus designed to stimulate a systemic anti-tumor T cell response. This innovative approach enables the conversion of oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without the need for multiple genetically modified viruses. Additionally, Valo Therapeutics is working on other strategies, such as PeptiENV, to enhance therapeutic responses to enveloped oncolytic viruses across various cancer types. By utilizing tumor-specific peptides, the company aims to elicit a robust adaptive immune response, potentially providing lasting immunity against multiple cancers and improving patient outcomes.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Quanturi Oy is a Finnish company founded in 2016 and headquartered in Espoo, specializing in continuous monitoring solutions for fermentable products. The company develops and markets connected objects and systems for data analysis, focusing on agricultural, forestry, and waste management sectors. Its product offerings include wireless monitoring systems for compost temperature, grain management, hay monitoring, and other industrial temperature applications. Quanturi Oy also sells its products online and has expanded its presence to several countries, including France, Great Britain, the Netherlands, Switzerland, Italy, and Belgium.

Quanturi Oy is a Finnish company founded in 2016 and headquartered in Espoo, specializing in continuous monitoring solutions for fermentable products. The company develops and markets connected objects and systems for data analysis, focusing on agricultural, forestry, and waste management sectors. Its product offerings include wireless monitoring systems for compost temperature, grain management, hay monitoring, and other industrial temperature applications. Quanturi Oy also sells its products online and has expanded its presence to several countries, including France, Great Britain, the Netherlands, Switzerland, Italy, and Belgium.

Surgify is engaged in the development of an innovative technology aimed at enhancing bone surgery outcomes. This technology focuses on protecting proximal soft structures during surgical procedures, thereby minimizing the risk of complications such as bleeding, infections, and nerve injuries. By collaborating closely with the Neurosurgical Department of Helsinki University Central Hospital, Surgify ensures that its solutions are informed by the needs of clinicians. The company is currently preparing to commercialize its technology, with support from the Finnish Funding Agency for Innovation. Through its advancements, Surgify aims to reduce patient suffering and improve overall quality of life for individuals undergoing bone surgery.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Carbo Culture Oy, founded in 2016 and based in Helsinki, Finland, specializes in producing biochar from waste biomass by employing a carbon sequestration process that captures carbon dioxide from the atmosphere. The company transforms orchard waste into high-quality biochar using patented reactors, which serves various applications, including soil enhancement and contamination remediation. This biochar helps improve soil health by retaining water and nutrients, while also supporting beneficial microorganisms. Additionally, Carbo Culture's innovative approach generates renewable energy and contributes to the creation of significant carbon credits, promoting sustainable practices in agriculture and construction.

Comptek Solutions Oy, founded in 2017 and based in Turku, Finland, specializes in developing advanced surface engineering technology known as Kontrox. This quantum-level process is designed to create defect-free surfaces for compound semiconductor devices, addressing the critical issues of oxidation that lead to performance limitations in products like MicroLEDs, lasers, and power electronics. By improving the crystalline quality of III-V-based semiconductors, Kontrox technology significantly enhances device performance, achieving notable improvements such as a 250% increase in efficiency and a 90-fold reduction in power consumption. Comptek Solutions has applications across various sectors, including optoelectronics and radio frequency technologies. The company has gained recognition for its innovative approach, receiving a Horizon2020 SME phase I grant from the EU in 2018 and being shortlisted as a top semiconductor spinoff in the inaugural Spinoff Prize competition by Nature Research in 2020.

Comptek Solutions Oy, founded in 2017 and based in Turku, Finland, specializes in developing advanced surface engineering technology known as Kontrox. This quantum-level process is designed to create defect-free surfaces for compound semiconductor devices, addressing the critical issues of oxidation that lead to performance limitations in products like MicroLEDs, lasers, and power electronics. By improving the crystalline quality of III-V-based semiconductors, Kontrox technology significantly enhances device performance, achieving notable improvements such as a 250% increase in efficiency and a 90-fold reduction in power consumption. Comptek Solutions has applications across various sectors, including optoelectronics and radio frequency technologies. The company has gained recognition for its innovative approach, receiving a Horizon2020 SME phase I grant from the EU in 2018 and being shortlisted as a top semiconductor spinoff in the inaugural Spinoff Prize competition by Nature Research in 2020.

Carbo Culture Oy, founded in 2016 and based in Helsinki, Finland, specializes in producing biochar from waste biomass by employing a carbon sequestration process that captures carbon dioxide from the atmosphere. The company transforms orchard waste into high-quality biochar using patented reactors, which serves various applications, including soil enhancement and contamination remediation. This biochar helps improve soil health by retaining water and nutrients, while also supporting beneficial microorganisms. Additionally, Carbo Culture's innovative approach generates renewable energy and contributes to the creation of significant carbon credits, promoting sustainable practices in agriculture and construction.

IQM is the pan-European leader in building quantum computers. IQM delivers on-premises quantum computers for supercomputing data centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique application-specific, co-design approach. IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is also building a quantum computer in Germany. This computer will be integrated into an HPC supercomputer to create a quantum accelerator for future scientific research. IQM has over 190+ employees with offices in Paris, Madrid, Munich, and Espoo.

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing innovative treatments for medical conditions with significant unmet needs. The company's pipeline includes drug candidates targeting acute trauma, cancer growth, and inflammatory diseases. Its lead product, Traumakine, is a recombinant human interferon beta-1a currently undergoing Phase III clinical trials for the treatment of acute respiratory distress syndrome (ARDS). Another significant candidate, Clevegen, is an immunotherapy designed to inhibit tumor growth and metastasis by targeting the tumor immune suppressor molecule. Additionally, Faron is developing D-ARDS, a diagnostic tool for assessing ARDS severity and monitoring patient outcomes. Established in 2003, Faron Pharmaceuticals collaborates with the MediCity unit at Turku University Medical School to further its research and development efforts.

Neuro Event Labs is a Finnish medical technology growth company. The company’s main product monitors epilepsy patients at home and in hospital. Accurate epilepsy seizure data is collected, analyzed and relayed to the patient’s physician, who makes individual treatment decisions based on the reports. The solution has been developed on close cooperation with leading Finnish hospitals.

IQM is the pan-European leader in building quantum computers. IQM delivers on-premises quantum computers for supercomputing data centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique application-specific, co-design approach. IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is also building a quantum computer in Germany. This computer will be integrated into an HPC supercomputer to create a quantum accelerator for future scientific research. IQM has over 190+ employees with offices in Paris, Madrid, Munich, and Espoo.

Neuro Event Labs is a Finnish medical technology growth company. The company’s main product monitors epilepsy patients at home and in hospital. Accurate epilepsy seizure data is collected, analyzed and relayed to the patient’s physician, who makes individual treatment decisions based on the reports. The solution has been developed on close cooperation with leading Finnish hospitals.

Aiforia Technologies, founded in 2013 as a spin-off from the Finnish Institute for Molecular Medicine at the University of Helsinki, specializes in cloud-based microscopy and pathology. The company offers the Aiforia® Platform, which combines deep learning artificial intelligence with high-performance cloud computing to enhance image-based diagnostics. Aiforia's solutions aim to increase efficiency and scalability in medical image analysis, supporting pathologists and scientists in both preclinical and clinical settings. By providing highly accurate and consistent data, Aiforia facilitates new discoveries and clinical decision-making across various disciplines, including oncology and neuroscience. The platform's image-agnostic capabilities allow it to extend its applications beyond traditional boundaries, positioning Aiforia as a leader in advancing medical imaging technology.

SSH Communications Security Oyj specializes in enterprise cybersecurity solutions aimed at helping organizations, particularly in the financial sector, manage and secure access to critical data, applications, and services globally. Founded in 1995 by Tatu Ylönen, who developed the widely adopted Secure Shell protocol, the company offers a range of products, including PrivX for access management in multi-cloud environments, Universal SSH Key Manager for managing SSH keys and certificates, Tectia SSH for secure file transfers and remote administration, and NQX Firewall for high-security applications. With a customer base exceeding 3,000 worldwide, SSH Communications Security focuses on providing security, compliance, and operational efficiency in complex enterprise environments. The company operates through direct sales and online channels, deriving a significant portion of its revenue from Finland while serving clients across various regions, including the Americas, Asia-Pacific, Europe, and the Middle East.

RePack is a company based in Helsinki, Finland, that specializes in manufacturing reusable and recyclable packaging solutions for online retailers and shoppers. Founded in 2013, RePack offers durable packaging bags made from materials such as polypropylene, polyethylene, and cardboard, which can be conveniently returned for recycling. The innovative system encourages customers to participate in sustainability efforts by rewarding them with vouchers for future purchases when they return the packaging. This model not only enhances the customer experience but also aims to reduce waste and carbon emissions. RePack's packaging is designed to be folded into a letter-sized format for easy return via local postal systems, making it a practical option for eCommerce businesses looking to demonstrate their commitment to sustainability.

Valtavalo Ltd was founded in 2008 to develop, manufacture and supply energy-efficient lighting solutions in Finland and globally. By concentrating on large volumes and clients, Valtavalo, as the largest LED tube manufacturer in the Northern Countries, can set competitive prices for new and advanced technologies, which have often in the past been regarded as too expensive.

Imaqen Ltd. is a Finnish healthcare technology company developing a new pre-screening solution for early detection of cancer. The innovation offers a non-invasive patient examination and it is suitable for use in wide range of healthcare facilities. The utilised method is protected by patents. Their team consists of experienced diagnostic imaging and clinical research professionals with solid track records in successful product development and global sales and marketing.

Medicortex Finland is developing the first, non-invasive, point-of-care diagnostic test for Traumatic Brain Injury and concussion. Problem: A Traumatic Brain Injury (TBI) happens when an external force to the head causes damage to the brain tissue. Mild TBI, which is also known as concussion, is difficult to diagnose with current diagnostic methods such as CT and MRI scans. Solution: Medicortex is working towards the incorporation of brain injury biomarkers into a hand-held diagnostic kit, which will give a reliable result rapidly and will not require medical professionals to interpret the result. Business: We identified a unique biomarker that can be detected from urine and saliva. With strong clinical evidence and protected idea, we are willing to negotiate with bigger diagnostic companies for collaboration on manufacturing and distribution. Market: Customers include hospitals, emergency rooms, paramedics and first responders, military paramedics, sports teams (especially contact sports such as rugby, American football, ice hockey), schools, pharma and insurance companies. Accomplishments: We have completed three clinical trials which have demonstrated the ability of the proprietary biomarker to distinguish TBI patients from healthy controls. The company has received grant funding from US Department of Defense (twice), European Union and Finnish Government.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.